The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on groundbreaking therapies and complex drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the promise for game-changing treatments and significant returns is undeniable, the associated risks are also significant